Hostname: page-component-848d4c4894-wg55d Total loading time: 0 Render date: 2024-04-30T16:07:46.908Z Has data issue: false hasContentIssue false
  • English
  • Français

Perspective from Clinical Research: Ethical Issues in Alzheimer's Disease Research

Published online by Cambridge University Press:  01 January 2021

Jacobo Mintzer
Get access Rights & Permissions [Opens in a new window]

Abstract

This paper attempts to bring to the attention of the readers a concept that broadens ethical considerations for Alzheimer's disease research. We propose we move away from the ethical paradigm that focuses on avoidance of coercion for participation in studies as well as privacy and safety to a more inclusive paradigm that will not only include the principles outlined above but will also guarantee access to new treatments for individuals that participate in research and other members of society. Specifically, if the research being performed results in a new treatment for Alzheimer's disease, would the individuals participating in the research and other members of their community have access to and benefit from these treatments, given the availability of financial and other resources in the society that will allow for the implementation of these treatments. This paper will propose a model that will facilitate the achievement of these broader ethical considerations.

Type
Symposium 2 Articles
Information
Journal of Law, Medicine & Ethics , Volume 46 , Issue 3: The Medicalization of Poverty; Perspectives of Alzheimer's Disease: Ethical, Legal, and Social Issues , Fall 2018 , pp. 699 - 703
Copyright
Copyright © American Society of Law, Medicine and Ethics 2018

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Dharmarajan, T. S. and Gunturu, S. G., “Alzheimer's Disease: A Healthcare Burden of Epidemic Proportion,” American Health & Drug Benefits 2, no. 1 (2009): 39-47.Google Scholar
Ortman, J. M., Velkoff, V. A., and Hogan, H., An Aging Nation: The Older Population in the United States, Population Estimates and Projections, US Census (May 2014).Google Scholar
Id.Google Scholar
Vincent, G. K. and Velkoff, V. A., The Next Four Decades: The Older Population in the United States: 2010 to 2050, US Census (May 2010): at 25-1138, available at <https://www.census.gov/prod/2010pubs/p25-1138.pdf> (last visited August 6, 2018).Google Scholar
Id.Google Scholar
Id.Google Scholar
Id.Google Scholar
Banerjee, S., “The Macroeconomics of Dementia: Will the World Economy Get Alzheimer's Disease?” Archives of Medical Research 43, no. 8 (2012): 705-709.CrossRefGoogle Scholar
Harford, T., The Undercover Economist Strikes Back: How to Run-or Ruinan Economy (New York: Riverhead, 2014).Google Scholar
Eichengreen, B., Feldman, R., Liebman, J., et al., Public Debts: Nuts, Bolts and Worries (Geneva: ICMB, 2011).Google Scholar
Klunk, W. E., et al., “Imaging Brain Amyloid in Alzheimer's Disease with Pittsburgh Compound-B,” Annals of Neurology 55, no. 3 (2004): 306-319.Google Scholar
Id.Google Scholar
Office of the Actuary, National Health Statistics. National Health Expenditure Data: Health Expenditures by State of Residence, Centers for Medicare and Medicaid Services, December 2011.Google Scholar
Forest Laboratories (Allergan), “NAMENDA-Memantine Hydrochloride Tablet,” Contract Pharmacy Services – PA, April 1995.Google Scholar
Design Data Decisions, “Spaghetti Plots with ggplot2 and ggvis,” August 2015, available at <https://designdatadecisions.wordpress.com/2015/08/19/spaghetti-plots-with-ggplot2-and-ggvis/> (last visited August 6, 2018).+(last+visited+August+6,+2018).>Google Scholar